

SPECTRUM PHARMACEUTICALS INC

Form 8-K

April 21, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934**

April 21, 2004 (April 20, 2004)  
Date of Report (Date of earliest event reported)  

---

**SPECTRUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other Jurisdiction  
of Incorporation)

**000-28782**  
(Commission File Number)

**93-0979187**  
(IRS Employer  
Identification Number)

**157 Technology Drive**  
**Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**(949) 788-6700**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

**1**

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required Regulation FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required Regulation FD Disclosure.**

On April 21, 2004, we issued a press release announcing that we agreed to sell approximately 3.2 million shares of our common stock for aggregate proceeds of approximately \$25 million to select institutional investors in a private placement transaction, subject to certain conditions. In addition, purchasers of the common stock will receive warrants to purchase up to approximately 1.1 million shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, *Pro Forma* Financial Information and Exhibits.**

(c) Exhibits

<b><u>Exhibits:</u></b>	<b><u>Description of Document</u></b>
99.1	Press Release dated April 21, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 21, 2004

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Rajesh C. Shrotriya

Name: Rajesh C. Shrotriya, M.D.  
Title: Chairman, Chief Executive Officer and  
President

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibits:</u></b>	<b><u>Description of Document</u></b>
99.1	Press Release dated April 21, 2004.